Uflex Ltd Q2 FY2024 Concall Summary

Key Takeaways

• EBITDA recovery from a low base: EBITDA jumped 33.6% QoQ, lifting margins ~270 bps to 12%, driven by volume growth and a sharp ~700 bps sequential margin recovery in overseas operations.
• Europe is the open wound: Revenue fell 11.9% YoY as European demand stayed weak on high energy and interest costs, and management cannot give clear guidance there until Q4.
• Nigeria and Egypt are the margin swing factors: A new 30% import duty in Nigeria and dollar shortages in Egypt created local-currency advantages that materially boosted overseas profitability this quarter.
• India’s volume is strong, but pricing is not: India produced its highest-ever packaging films volumes, yet standalone margins fell sequentially because industry overcapacity is crushing prices.
• What to watch next quarter: Whether the 12%–12.5% EBITDA margin target holds in Q3, any sign of European demand stabilization, and the Q4 guidance update that management says will clarify the overseas listing path.

Overseas Turnaround: Nigeria, Egypt and the US

• Overseas EBITDA margins recovered ~700 bps sequentially, a swing management attributed to three structural tailwinds and no one-off items.
• Nigeria’s 30% import duty on BOPET was imposed during Q2, protecting local manufacturers like Uflex by forcing customers who lack dollar access to buy locally.
• Egypt’s dollar shortage gives Uflex a local-currency price advantage, as imported alternatives become prohibitively expensive in the parallel forex market.
• US pricing improved alongside a 6.6% volume increase in packaging films, contributing to the overseas margin lift.
• Nigeria’s demand-supply mismatch in dollars persists: small customers cannot access forex, but Uflex’s global reach lets it manage the dislocation better than local competitors.

Rajesh Bhatia: "if Q1 was the lowest point in this I think Q2 has shown much better numbers where the EBITDA is up healthy by about 270 bps to 12%"

Europe: The Anchor on Revenue

• Consolidated revenue fell 11.9% YoY, with Europe the primary drag as demand stayed suppressed by elevated energy costs and higher interest rates.
• Management cannot give better guidance on Europe until Q4, calling it an “area of uncertainty” with no near-term visibility on a demand recovery.
• America markets, by contrast, are expected to keep improving in Q3 and Q4 as interest rates freeze or decline, which should unlock better demand in coming quarters.
• India demand remains strong on volume, partially offsetting the European weakness, though pricing pressure dilutes the revenue benefit.

Rajesh Bhatia: "The Europe remains an area of uncertainty driven by the lack of demand because of the issues relating to energy cost as well as the EMI higher interest cost"

India: Volume Leader, Margin Laggard

• India produced its highest-ever packaging films volumes in Q2 versus Q1, but standalone margins fell sequentially because industry overcapacity drove pricing down.
• The integrated model helped the India business report what management called “decent” performance despite the pricing headwind.
• Flexible packaging mix improved sharply: laminate production rose 14.5% QoQ, value-added holographic films jumped 27% QoQ, and blended growth reached 20.9% QoQ.
• Aseptic packaging dragged on standalone margins because Q2 is a seasonally lean quarter; the debottlenecking expansion from 700 crore to 1,200 crore packs is now delayed to September/October 2024 due to late equipment arrival.
• Dharwad’s volume contribution in Q2 was flat versus Q1, with no further additions from the facility.

Capacity Expansion: Pet Chips, Egypt, and the Million-Tonne Question

• Panipat pet chips plant: A ₹587 Cr capex project with commercial production targeted by end of FY2024 or early April.
• Egypt facility: Commissioning expected by end of FY2024 or slightly earlier.
• Million-tonne capacity aspiration: Timing is undecided; management will not take a view on further expansion until clarity emerges on conditions in Europe, America and India.
• No other India expansions are planned beyond Panipat and Egypt as of now.
• Aseptic liquid packaging overseas: The company is exploring markets but will first complete the India debottlenecking before committing to further investments, though it claims agility if opportunities arise given the better margin profile.

Rajesh Bhatia: "the timing of that is still not sort of decided and presently there are issues in Europe, America and India so I think once the clear emerges only then any view can be taken on any further capacity expansion"

Sustainability: PCR, Biodegradables and Policy Tailwinds

• Mexico PCR facility: A large plant capable of producing 1,500 tonnes per month has been completed; management expects near-100% capacity utilization within the next year.
• Poland multilayer plastic recycling plant: Set up to convert waste laminates into plastic granules.
• Biodegradable packaging films: Developed in-house, with a small Dubai facility producing the enzymes added during film manufacturing.
• India’s EPR policy requires brand owners to commit to recycling or biodegradable material, starting at 20% and scaling to 100% over four to five years; if enforced, management sees huge potential for biodegradable packaging.
• No government incentives currently exist in India to promote sustainable packaging or recycling, per management.
• A small pilot plant for sustainable packaging operates in India.

Rajesh Bhatia: "aided by the policies this is going to be the next big thing in the packaging films business. The biodegradable packaging which means that if you throw the package after eating roadside it will become a fertilizer at the end of it assigned life cycle."

Balance Sheet & Overseas Listing

• Net debt stands at ₹4,750 Crores; no long-term borrowings have been added in India, and ~₹550 Crores in annual amortization will keep reducing it.
• Debt trajectory: Some additional debt may be taken for the new pet chips plants, but considering amortization, net debt is expected to remain within ₹5,000 Crores, with a reduction beginning from 2026 once expansion projects conclude.
• Overseas listing is on hold because markets remain soft and overseas EBITDA needs to normalize; FY2025 is seen as a better window to revive the process. At the time of initial planning, overseas EBITDA visibility was at least $200 million, but that visibility is currently absent. Q4 will provide good guidance on offshore volumes, revenues and profitability.

Guidance & Commitments

Key Metrics